Spring 2020 QuestQUEST is a FREE newsletter published three times a year by the Urological Research Foundation. It informs readers of the latest advances in urologic research, especially prostate cancer treatment.

Please click here to subscribe to QUEST.

QUEST is a free newsletter, but we appreciate your support in helping the URF bring this publication to its readers.

The PROMIS Trial: Using MRI to Avoid Unnecessary Biopsies

Typically, men with elevated PSAs have transrectal ultrasound-guided (TRUS) prostate biopsies to look for prostate cancer. However, TRUS biopsies can have errors in diagnosis because tissue samples are taken at random, and they cannot confirm whether a cancer is aggressive…

Read More

Midlife Baseline PSA Predicts: Lethal Prostate Cancer

A case-control study found that a midlife PSA above the median strongly predicted future lethal prostate cancer. The authors suggested that risk-stratified screening on the basis of midlife PSA should be considered for men ages 45 to 59 years. The…

Read More

Subscribe to Quest